{"id":"https://openalex.org/W2809442252","doi":"https://doi.org/10.1017/s1092852918000093","title":"109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis","display_name":"109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis","publication_year":2018,"publication_date":"2018-02-01","ids":{"openalex":"https://openalex.org/W2809442252","doi":"https://doi.org/10.1017/s1092852918000093","mag":"2809442252"},"language":"en","primary_location":{"id":"doi:10.1017/s1092852918000093","doi":"https://doi.org/10.1017/s1092852918000093","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s1092852918000093","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/1358DF1E7F45F90B074B962711B8EADD/S1092852918000093a.pdf/div-class-title-109-comparative-efficacy-and-tolerability-of-lurasidone-versus-other-oral-atypical-antipsychotics-for-pediatric-schizophrenia-a-network-meta-analysis-div.pdf","source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/1358DF1E7F45F90B074B962711B8EADD/S1092852918000093a.pdf/div-class-title-109-comparative-efficacy-and-tolerability-of-lurasidone-versus-other-oral-atypical-antipsychotics-for-pediatric-schizophrenia-a-network-meta-analysis-div.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002872855","display_name":"Celso Arango","orcid":"https://orcid.org/0000-0003-3382-4754","observed_orcids":["https://orcid.org/0000-0003-3382-4754"]},"institutions":[{"id":"https://openalex.org/I2960094004","display_name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n","ror":"https://ror.org/0111es613","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2960094004","https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Celso Arango","raw_affiliation_strings":["Chair Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Universidad Complutense, IBERSAM, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chair Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Universidad Complutense, IBERSAM, Madrid, Spain","institution_ids":["https://openalex.org/I2960094004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003582081","display_name":"Daisy Ng\u2010Mak","orcid":"https://orcid.org/0000-0002-9802-7660","observed_orcids":["https://orcid.org/0000-0002-9802-7660"]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daisy Ng-Mak","raw_affiliation_strings":["Senior Director, Global Health Economics & Outcomes Research, Sunovion Pharmaceuticals Inc, Marlborough, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Senior Director, Global Health Economics & Outcomes Research, Sunovion Pharmaceuticals Inc, Marlborough, MA, USA","institution_ids":["https://openalex.org/I4210122020"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033095688","display_name":"Elaine Finn","orcid":"https://orcid.org/0000-0002-6922-899X","observed_orcids":["https://orcid.org/0000-0002-6922-899X"]},"institutions":[{"id":"https://openalex.org/I28927889","display_name":"IQVIA (United Kingdom)","ror":"https://ror.org/040g76k92","country_code":"GB","type":"company","lineage":["https://openalex.org/I28927889","https://openalex.org/I4210108991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Elaine Finn","raw_affiliation_strings":["QuintilesIMS, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"QuintilesIMS, London, United Kingdom","institution_ids":["https://openalex.org/I28927889"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Aidan Byrne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28927889","display_name":"IQVIA (United Kingdom)","ror":"https://ror.org/040g76k92","country_code":"GB","type":"company","lineage":["https://openalex.org/I28927889","https://openalex.org/I4210108991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Aidan Byrne","raw_affiliation_strings":["QuintilesIMS, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"QuintilesIMS, London, United Kingdom","institution_ids":["https://openalex.org/I28927889"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020259891","display_name":"Krithika Rajagopalan","orcid":"https://orcid.org/0000-0002-4878-0822","observed_orcids":["https://orcid.org/0000-0002-4878-0822"]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Krithika Rajagopalan","raw_affiliation_strings":["Head of Global HEOR, Global Health Economics and Outcomes Research, Sunovion Pharmaceuticals, Marlborough, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Head of Global HEOR, Global Health Economics and Outcomes Research, Sunovion Pharmaceuticals, Marlborough, MA","institution_ids":["https://openalex.org/I4210122020"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066553937","display_name":"Antony D Loebel","orcid":"https://orcid.org/0000-0002-7591-8647","observed_orcids":["https://orcid.org/0000-0002-7591-8647"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Antony Loebel","raw_affiliation_strings":["Executive Vice President, Chief Medical Officer, Research & Development, Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Executive Vice President, Chief Medical Officer, Research & Development, Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3550,"currency":"USD","value_usd":3550},"apc_paid":null,"fwci":0.1965,"has_fulltext":true,"cited_by_count":2,"citation_normalized_percentile":{"value":0.5651565,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"23","issue":"1","first_page":"70","last_page":"71"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10854","display_name":"Bipolar Disorder and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lurasidone","display_name":"lurasidone","score":0.9599999785423279},{"id":"https://openalex.org/keywords/pediatric-schizophrenia","display_name":"pediatric schizophrenia","score":0.9869999885559082},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.9990000128746033},{"id":"https://openalex.org/keywords/comparative-efficacy","display_name":"drug efficacy comparison","score":0.6209999918937683},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.9670000076293945},{"id":"https://openalex.org/keywords/weight-gain","display_name":"weight gain","score":0.8769999742507935},{"id":"https://openalex.org/keywords/extrapyramidal-symptoms","display_name":"extrapyramidal symptoms","score":0.9380000233650208},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.9610000252723694},{"id":"https://openalex.org/keywords/positive-and-negative-syndrome-scale","display_name":"PANSS","score":0.7210000157356262},{"id":"https://openalex.org/keywords/cgi-s","display_name":"CGI-S","score":0.6480000019073486},{"id":"https://openalex.org/keywords/clozapine","display_name":"clozapine","score":0.8539999723434448},{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":0.9070000052452087},{"id":"https://openalex.org/keywords/aripiprazole","display_name":"aripiprazole","score":0.8159999847412109},{"id":"https://openalex.org/keywords/ziprasidone","display_name":"ziprasidone","score":0.75},{"id":"https://openalex.org/keywords/paliperidone","display_name":"paliperidone","score":0.8360000252723694},{"id":"https://openalex.org/keywords/quetiapine","display_name":"quetiapine","score":0.8489999771118164},{"id":"https://openalex.org/keywords/risperidone","display_name":"risperidone","score":0.9120000004768372},{"id":"https://openalex.org/keywords/asenapine","display_name":"asenapine","score":0.9929999709129333}],"concepts":[{"id":"https://openalex.org/C2776701107","wikidata":"https://www.wikidata.org/wiki/Q416992","display_name":"Lurasidone","level":4,"score":0.9189223647117615},{"id":"https://openalex.org/C2779626651","wikidata":"https://www.wikidata.org/wiki/Q416545","display_name":"Asenapine","level":4,"score":0.893951416015625},{"id":"https://openalex.org/C2780211496","wikidata":"https://www.wikidata.org/wiki/Q411188","display_name":"Aripiprazole","level":3,"score":0.8648450374603271},{"id":"https://openalex.org/C2780634440","wikidata":"https://www.wikidata.org/wiki/Q408535","display_name":"Quetiapine","level":3,"score":0.7702240347862244},{"id":"https://openalex.org/C2777126507","wikidata":"https://www.wikidata.org/wiki/Q423292","display_name":"Paliperidone","level":4,"score":0.7116907835006714},{"id":"https://openalex.org/C2777270317","wikidata":"https://www.wikidata.org/wiki/Q205517","display_name":"Ziprasidone","level":4,"score":0.6800943613052368},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6306424736976624},{"id":"https://openalex.org/C2780057945","wikidata":"https://www.wikidata.org/wiki/Q412443","display_name":"Risperidone","level":3,"score":0.598082959651947},{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.5572187900543213},{"id":"https://openalex.org/C2780135775","wikidata":"https://www.wikidata.org/wiki/Q7233251","display_name":"Positive and Negative Syndrome Scale","level":3,"score":0.5515756011009216},{"id":"https://openalex.org/C2780864610","wikidata":"https://www.wikidata.org/wiki/Q221361","display_name":"Clozapine","level":3,"score":0.524355411529541},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5242224931716919},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5146325826644897},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5141782760620117},{"id":"https://openalex.org/C2778999636","wikidata":"https://www.wikidata.org/wiki/Q418785","display_name":"Amisulpride","level":4,"score":0.5063940286636353},{"id":"https://openalex.org/C2780616385","wikidata":"https://www.wikidata.org/wiki/Q1385411","display_name":"Extrapyramidal symptoms","level":4,"score":0.473096638917923},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.43161600828170776},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.36559051275253296},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.35882025957107544},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.3529255986213684},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.1949649155139923},{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.08643877506256104}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1017/s1092852918000093","doi":"https://doi.org/10.1017/s1092852918000093","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s1092852918000093","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/1358DF1E7F45F90B074B962711B8EADD/S1092852918000093a.pdf/div-class-title-109-comparative-efficacy-and-tolerability-of-lurasidone-versus-other-oral-atypical-antipsychotics-for-pediatric-schizophrenia-a-network-meta-analysis-div.pdf","source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1017/s1092852918000093","doi":"https://doi.org/10.1017/s1092852918000093","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s1092852918000093","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/1358DF1E7F45F90B074B962711B8EADD/S1092852918000093a.pdf/div-class-title-109-comparative-efficacy-and-tolerability-of-lurasidone-versus-other-oral-atypical-antipsychotics-for-pediatric-schizophrenia-a-network-meta-analysis-div.pdf","source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2809442252.pdf","grobid_xml":"https://content.openalex.org/works/W2809442252.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2991400056","https://openalex.org/W4237444251","https://openalex.org/W4212792635","https://openalex.org/W2078053761","https://openalex.org/W3048065947","https://openalex.org/W2600413000","https://openalex.org/W2092061263","https://openalex.org/W7118814707","https://openalex.org/W3093032938","https://openalex.org/W4205653171"],"abstract_inverted_index":{"Abstract":[0],"Study":[1],"Objective":[2],"This":[3,251],"analysis":[4],"assessed":[5],"the":[6,18,32,42,47,94,231],"relative":[7,150],"efficacy":[8,43],"and":[9,44,65,75,89,106,132,184,197,209,213],"tolerability":[10,45],"of":[11,20,34,46,200,219,227,233],"lurasidone":[12,149,208,236],"versus":[13],"other":[14],"atypical":[15,49,228],"antipsychotics":[16,229],"in":[17,145],"treatment":[19,33,87,232],"pediatricschizophrenia.":[21],"Methods":[22],"A":[23,37],"systematic":[24],"literature":[25],"review":[26],"identified":[27],"13":[28],"randomized-controlled":[29],"trials":[30],"for":[31,103,109,127,148,194,207,230],"pediatric":[35],"schizophrenia.":[36],"Bayesian":[38],"network":[39,225],"meta-analysis":[40,226],"compared":[41,124],"following":[48],"antipsychotics:":[50],"aripiprazole,":[51,196],"asenapine,":[52],"clozapine,":[53,195],"lurasidone,":[54],"olanzapine,":[55],"paliperidone,":[56,214],"quetiapine,":[57],"risperidone,":[58],"andziprasidone.":[59],"Patients":[60],"were":[61,98,153,190,205],"7-17":[62],"years":[63],"old":[64],"trial":[66],"duration":[67],"ranged":[68],"from":[69,93,141],"6-12":[70],"weeks.":[71],"Outcomes":[72],"included":[73],"Positive":[74],"Negative":[76],"Syndrome":[77],"Scale":[78],"(PANSS),":[79],"Clinical":[80],"Global":[81],"Impressions-Severity":[82],"(CGI-S),":[83],"weight":[84,146,244],"gain,":[85],"all-cause":[86,201,220],"discontinuation,":[88],"extrapyramidal":[90],"symptoms.":[91],"Results":[92,118],"fixed":[95],"effect":[96],"models":[97],"reported":[99],"as":[100,154],"mean":[101],"differences":[102,144],"continuous":[104],"outcomes":[105],"odds":[107],"ratios":[108],"binary":[110],"outcomes;":[111],"each":[112],"with":[113,125,239],"a":[114],"95%":[115],"credible":[116],"interval.":[117],"Lurasidone":[119],"had":[120,216],"significantly":[121],"greater":[122],"improvement":[123],"placebo":[126],"PANSS":[128],"(-7.95":[129],"[-11.76,":[130],"-4.16])":[131],"CGI-S":[133],"(-0.44":[134],"[-0.67,":[135],"-0.22]),":[136],"but":[137,242],"did":[138],"not":[139],"differ":[140],"comparators.":[142,248],"The":[143],"gain":[147,245],"to":[151],"comparators":[152],"follows:":[155],"clozapine":[156],"(-3.81kg":[157],"[-8.03,":[158],"0.42]),":[159],"olanzapine":[160],"(-3.62kg":[161],"[-4.84,":[162],"-2.41]),":[163],"quetiapine":[164],"(-2.13kg":[165],"[-3.20,":[166],"-1.08]),":[167],"risperidone":[168],"(-1.16kg":[169],"[-2.14,":[170],"-0.17]),":[171],"asenapine":[172],"(-0.98kg":[173],"[-1.71,":[174],"-0.24]),":[175],"paliperidone":[176],"(-0.85kg":[177],"[-1.57,":[178],"-0.14]),":[179],"aripiprazole":[180,212],"(-0.15kg":[181],"[-0.88,":[182],"0.58]),":[183],"ziprasidone":[185],"(0.38kg":[186],"[-0.49,":[187],"1.24]);":[188],"all":[189],"statistically":[191],"significant":[192],"except":[193,211],"ziprasidone.":[198],"Rates":[199],"discontinuation":[202],"andextrapyramidal":[203],"symptoms":[204],"similar":[206,240],"comparators,":[210],"which":[215],"higher":[217],"rates":[218],"discontinuation.":[221],"Conclusions":[222],"In":[223],"this":[224],"adolescent":[234],"schizophrenia,":[235],"was":[237,253],"associated":[238],"efficacy,":[241],"less":[243],"than":[246],"active":[247],"Funding":[249],"Acknowledgements":[250],"study":[252],"funded":[254],"by":[255],"Sunovion":[256],"Pharmaceuticals":[257],"Inc.":[258]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2018-06-29T00:00:00"}